Newsroom Articles Glossary SignalPoint Signal On-Call Home Subscribe to the Trendletter E-mail  Search        About Us             Services             Clients             Contact Us             עברית         Overview   Team   Signal America   Retail Advisory Panel   Medical Advisory Panel   Market Strategy   Partner & Sales Channel Development   Marketing Communications   Signal ON-CALL   Client List   Client Stories   Contact Info   Directions News   Australia-traded Karmelsonix mulls TASE listing The Wheezometer developer's market value is $21 million. Sources inform ''Globes'' that Wheezometer developer KarmelSonix Ltd. (ASX: KSX) is considering dual-listing on the Tel Aviv Stock Exchange (TASE). The company is also considering a Private Investment in Public Equity (PIPE) of several million dollars from Israeli and Australian investors ahead of the dual listing.   KarmelSonix develops asthma diagnostic devices based on the patient's wheezing, hacks, and coughs. The Wheezometer analyzes the sounds to provide data about the illness and severity of an attack, and recommends treatment.   Directions     Privacy Policy     Site Map     Tel: +972.72.260.7000 ©2010 The Trendlines Group Ltd. All rights reserved. This site contains material copyrighted by third parties.